Samit Hirawat, Bristol Myers Squibb CMO
#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot
NEW ORLEANS — Bristol Myers Squibb pulled back the curtain on its CAR-T cell therapy going after GPRC5D, and also released Phase I data for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
